A multinational study to establish the value of early adenosine technetium-99m sestamibi myo- cardial perfusion imaging in identifying a low-risk group for early hos- pital discharge after acute myocardial infarction. J Am Coll Cardiol. 2006;48:2448 57. 354. Shaw LJ, Peterson ED, Shaw LK, et al. Use of a prognostic treadmill score in identifying diagnostic coronary disease subgroups. Circulation. 1998;98:1622 30. 355. Morice MC, Serruys PW, Kappetein AP, et al. Outcomes in patients with de novo left main disease treated with either percutaneous coronary inter- vention using paclitaxel-eluting stents or coronary artery bypass graft treatment in the Synergy Between Percutaneous Coronary Intervention with TAXUS and Cardiac Surgery (SYNTAX) trial. Circulation. 2010;121:2645 53. 356. Kappetein AP, Feldman TE, Mack MJ, et al. Comparison of coronary bypass surgery with drug-eluting stenting for the treatment of left main and/or three-vessel disease: 3-year follow-up of the SYNTAX trial. Eur Heart J. 2011;32:2125 34. 357. Weintraub WS, Grau-Sepulveda MV, Weiss JM, et al. Comparative effec- tiveness of revascularization strategies. N Engl J Med. 2012;366:1467 76. 358. Velazquez EJ, Lee KL, Deja MA, et al. Coronary-artery bypass sur- gery in patients with left ventricular dysfunction. N Engl J Med. 2011;364:1607 16. 359. Bangalore S, Faxon DP. Coronary intervention in patients with acute coronary syndrome: does every culprit lesion require revascularization? Curr Cardiol Rep. 2010;12:330 7. 360. Brener SJ, Milford-Beland S, Roe MT, et al. Culprit-only or multives- sel revascularization in patients with acute coronary syndromes: an American College of Cardiology National Cardiovascular Database Registry report. Am Heart J. 2008;155:140 6. 361. Brener SJ, Murphy SA, Gibson CM, et al. Efficacy and safety of multi- vessel percutaneous revascularization and tirofiban therapy in patients with acute coronary syndromes. Am J Cardiol. 2002;90:631 3. 362. Palmer ND, Causer JP, Ramsdale DR, et al. 